menu search

Werewolf: q4 2023 data readout and enhancement of validated targets

Preliminary safety and biomarker results from the phase 1/1b study, using WTX-124 for the treatment of patients with solid tumors, expected Q4 of 2023...

August 25, 2023, 4:48 pm

Arbutus presents preliminary ab-729 and pegylated interferon alfa-2a combination data at the easl congress 2023

Treatment was generally well tolerated with continued HBsAg declines in some patients WARMINSTER, Pa., June 21, 2023 (GLOBE NEWSWIRE) — Arbutus Biop...

June 21, 2023, 6:01 am

Cytomx therapeutics to present preclinical data for conditionally activated interferon alpha-2b (cx-801) at the sitc 2022 annual meeting

- IND filing for CX-801 is anticipated in the second half of 2023 - - IND filing for CX-801 is anticipated in the second half of 2023 -...

November 7, 2022, 4:15 pm

Aim immunotech says study partner roswell park begins patient enrollment in ampligen and resistant melanoma phase 2 trial

AIM ImmunoTech Inc (NYSE:AIM) said its clinical development collaborator Roswell Park Comprehensive Cancer Center has commenced patient enrollment in ...

August 30, 2022, 9:08 am

Werewolf therapeutics shares jump on cancer product pact with jazz pharma

Jazz Pharmaceuticals plc (NASDAQ: JAZZ) has acquired exclusive global development and commercialization rights to Werewolf Therapeutics Inc's (NA...

April 7, 2022, 9:36 am


Search within

Pages Search Results: